Underuse of Oral anticoagulants in privately insured patients with atrial fibrillation: A population targeted by IMplementation of a randomized controlled trial to ImProve treatment with Oral AntiCoagulanTs in atrial fibrillation patients (IMPACT-AFib)

Tabs

Details

Basic Details

Date:

Friday, July 24, 2020

Type:

Publication

Description:

Many studies showing underuse of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) predated the advent of the non-vitamin K antagonist OACs. We retrospectively examined use of OACs in a large commercially insured population.

Materials:

American Heart Journal. 2020 Jul 24. doi.org/10.1016/j.ahj.2020.07.012

Additional Information

Contributors

Author(s):

Sana M. Al-Khatib, Sean D. Pokorney, Hussein R. Al-Khalidi, Kevin Haynes, Crystal Garcia, David Martin, Jennifer C. Goldsack, Thomas Harkins, Noelle M. Cocoros, Nancy D. Lin, Hana Lipowicz, Debbe McCall, Vinit Nair, Lauren Parlett, Cheryl N. McMahill-Walraven, Richard Platt, Christopher B. Granger

Corresponding Author:

Sana M. Al-Khatib; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
Email: alkha001@mc.duke.edu

Search form

News & Events

Underuse of Oral anticoagulants in privately insured patients with atrial fibrillation: A population targeted by IMplementation of a randomized controlled trial to ImProve treatment with Oral AntiCoagulanTs in atrial fibrillation patients (IMPACT-AFib)

Tabs